Immuno Cure BioTech在全国竞争其有前途的艾滋病毒/艾滋病脱氧核糖核酸疫苗时获得最高奖,并计划2028年商业化,进入第二阶段试验阶段。 Immuno Cure BioTech won top prize at a national competition for its promising HIV/AIDS DNA vaccine, advancing to Phase II trials with plans for 2028 commercialization.

Immuno Cure Biotech于2025年9月27日因使用香港大学的技术研制的艾滋病毒/艾滋病治疗DNA疫苗ICVAX荣获GBA创业竞赛大奖。 Immuno Cure BioTech won the Grand Prize at the National GBA Entrepreneurship Competition on September 27, 2025, for its HIV/AIDS therapeutic DNA vaccine, ICVAX, developed with technology from the University of Hong Kong. 疫苗在第一阶段试验中取得了积极成果,并正在为第二阶段试验作准备。 The vaccine showed positive results in Phase I trials and is preparing for Phase II testing. 该公司总部设在香港,收到6 000万元人民币的投资意向书,目的是在2028年之前实现商业化,利用大湾地区的创新生态系统。 The company, based in Hong Kong, received a RMB 60 million investment expression of interest and aims for commercialization by 2028, leveraging the Greater Bay Area’s innovation ecosystem.